Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has shared an announcement.
BioDlink International Company Limited announced a sweeping board overhaul following a change in control after voluntary general cash offers resulted in WuXi XDC Cayman Inc. becoming its controlling shareholder. With effect from 29 April 2026, the existing chairperson, several executive, non-executive and independent non-executive directors, and multiple board committee leaders have resigned without reported disagreements, prompting a full reconfiguration of board governance.
On the same date, BioDlink appointed Dr. Jincai Li as executive director and new chairperson of the board, alongside four new non-executive and independent non-executive directors who will chair and populate key committees including nomination, audit, remuneration, and strategy and ESG. The reshuffled leadership signals a governance realignment under WuXi XDC’s control that may reshape the company’s strategic direction, risk oversight, and ESG priorities, with implications for how it is managed and positioned within the competitive biopharma landscape.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited, listed in Hong Kong, operates in the biopharmaceutical sector through its group subsidiaries. The company focuses on developing and commercializing biologic therapies, positioning itself within the broader life sciences and healthcare markets in Asia and globally.
Average Trading Volume: 2,431,970
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.57B
See more data about 1875 stock on TipRanks’ Stock Analysis page.